Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies

NCT05292664 is registered in ClinicalTrials.gov with Andrew E. Place, MD as lead sponsor.

NCT NCT05292664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05292664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies
Lead sponsor
Andrew E. Place, MD
Phase
Phase 1
Overall status
Recruiting
Start date
March 29, 2023
Completion date
July 2, 2030
Enrollment
30 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia of ambiguous lineage, acute leukemia of ambiguous lineage in relapse, acute lymphoblastic leukemia with failed remission, acute lymphoblastic leukemia, in relapse, lymphoblastic lymphoma, in relapse, lymphoblastic lymphoma, refractory, myelodysplastic syndromes, de novo, myelodysplastic syndromes, previously treated, myelodysplastic syndromes, secondary, therapy-related myelodysplastic syndrome, treatment-related acute myeloid leukemia